ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,612Medicare Part D Prescriptions Filled, Including Refills

Rank: 23 out of 1019

$723K Total Retail Price of All Prescriptions

Rank: 26 out of 1019

699 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
12% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

4% of this provider’s 699 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

0% of this provider’s 10,938 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$62 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
METOPROLOL TARTRATE 629 590 1 8
LISINOPRIL 626 566 2 2
SIMVASTATIN 562 547 3 5
AMLODIPINE BESYLATE 498 481 4 4
FUROSEMIDE 473 418 5 6
WARFARIN SODIUM 442 393 6 9
METOPROLOL SUCCINATE 439 426 7 1
ATORVASTATIN CALCIUM 300 285 8 10
CRESTOR 275 245 9 13
LEVOTHYROXINE SODIUM 258 242 10 25
HYDRALAZINE HCL 248 241 11 34
VYTORIN 247 247 12 62
PRADAXA 230 230 13 24
POTASSIUM CHLORIDE 228 221 14 15
CARVEDILOL 202 165 15 3
HYDROCHLOROTHIAZIDE 196 185 16 18
ATENOLOL 193 185 17 19
COUMADIN 190 181 18 54
CLOPIDOGREL 185 179 19 7
PRAVASTATIN SODIUM 173 172 20 16
DIOVAN 171 137 21 20
PLAVIX 137 133 22 11
ZETIA 137 133 22 30
AMLODIPINE BESYLATE-BENAZEPRIL 133 133 24 47
SERTRALINE HCL 131 127 25 94
DIGOXIN 128 124 26 14
AMIODARONE HCL 122 96 27 22
CITALOPRAM HBR 116 112 28 90
KLOR-CON M20 115 113 29 56
LOSARTAN POTASSIUM 107 106 30 17
METFORMIN HCL 100 93 31 42
NITROGLYCERIN PATCH 100 86 31 59
OMEPRAZOLE 96 96 33 41
JANTOVEN 95 82 34 73
TRIAMTERENE-HCTZ 94 92 35 57
ISOSORBIDE MONONITRATE ER 88 88 36 12
NIASPAN 84 72 37 33
LIPITOR 83 83 38 37
LOVASTATIN 83 79 38 44
BUMETANIDE 82 82 40 74
ZOLPIDEM TARTRATE 76 64 41 55
RANEXA 68 68 42 32
NEXIUM 66 54 43 52
DILTIAZEM 24HR ER 64 54 44 84
FELODIPINE ER 64 64 44 106
HYDROCODONE-ACETAMINOPHEN 63 51 S3 46 36
XARELTO 61 61 47 67
SOTALOL 60 46 48 35
RAMIPRIL 58 58 49 21
ENALAPRIL MALEATE 56 56 50 38
TERAZOSIN HCL 55 55 51 145
PANTOPRAZOLE SODIUM 51 51 52 46
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 29, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.